Sign in

CIK 0001668243

  • Non-accelerated filer
  • Smaller reporting company

UroGen Pharma Ltd.

Sign in to watch
Ticker
URGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
Israel
Entity type
Operating
Phone
+972 97707601
Business address
9 HA'TA'ASIYA ST, RA'ANANA, Israel, 4365007
  1. 4 Open-market sale Chief Medical Officer sold 107 shares at $16.32 ($1,746)
  2. 4 Open-market sale Chief Medical Officer sold 243 shares at $15.64 ($3,801)
  3. 4 Open-market sale Chief Medical Officer sold 103 shares at $15.30 ($1,576)
  4. 4/A Exercise or conversion Chief Executive Officer acquired 61,652 shares (option exercise)
  5. 4/A Exercise or conversion Chief Executive Officer acquired 35,229 shares (option exercise)
  6. 4/A Exercise or conversion Director acquired 3,241 shares (option exercise)
  7. 4/A Exercise or conversion Director acquired 1,030 shares (option exercise)
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Exercise or conversion Director acquired 2,211 shares (option exercise)
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Shares withheld for taxes Chief Executive Officer gave up 3,425 shares (to pay taxes)
  18. 4 Open-market buy Chief Financial Officer bought 2,500 shares at $15.85 ($39,625)
  19. 4 Open-market buy General Counsel bought 2,500 shares at $15.71 ($39,275)
  20. 4 Open-market sale Chief Medical Officer sold 243 shares at $20.00 ($4,860)

Page 7 of 12 · 233 filings